LimFlow

LimFlow is a private, venture-backed medical device company transforming the treatment of Critical Limb Ischemia, a growing clinical need in the face of the prevalence of diabetes, heart disease and an aging population. The LimFlow Percutaneous Deep Vein Arterialization (pDVA) System is designed to bypass blocked arteries in the leg and rush oxygenated blood back into the foot. For many patients, restoring perfusion in the lower limbs resolves chronic pain, improves quality of life, promotes wound healing and prevents major amputation.

SofinnovaCapital

The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.

SofinnovaMD Start

The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.

SofinnovaCrossover

The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.

SofinnovaIndustrial Biotech

Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.

SofinnovaTelethon

The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.

SofinnovaDigital Medicine

The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.

SofinnovaBiovelocita

The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.

Join our mailing list

Keep up to date with our latest news.

Required
Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.